menu search

Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical posters presented at AACR 2023 in April on HPN217, HPN328 and ProTriTAC™ development candidates Following $25 million financing in March, cash and equivalents of $61.4 […] The post Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update appeared first on ForexTV... Read More
Posted: May 11 2023, 20:30
Author Name: forextv
Views: 102533

Search within

Pages Search Results: